NCT07633470
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Recruiting
PHASE4Ages 50+InterventionalTreatmentAlpha Cognition, Inc
~150 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Zunveyl®
At a glance
Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over From Week 1 up to Week 12
+3 more outcomes measured
Conditions
Where it's being run
5 sites across 4 statesFlorida2
Illinois1
Missouri1
New York1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)From Week 1 up to Week 12
- Percentage of Participants who Discontinued due to AEsFrom Week 1 up to Week 12
- Number of Participants with Treatment Interruptions or Dose ReductionsFrom Week 1 up to Week 12
- Global Tolerability ScoreAt Weeks 1, 2, 4, 6, 8 12, and 17
Functional Assessment of Chronic Illness Therapy (FACIT) General Physical Well-Being domain Item 5 (GP5) will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Higher scores indicate greater bother from treatment side effects and worse treatment toxicity.